Management options of breast cancer related osteoporosis

Clinical Cases in Mineral and Bone Metabolism

Volumn 11, Issue 2, 2014, Pages 110-113

  Becorpi, Angelamaria ^a   Sisti, Giovanni ^b   Sorbi, Flavia ^b   Malosso, Elena Rita Magro ^b   Guaschino, Secondo ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bone resorption; Breast cancer; Drug therapy; Osteoporosis; Women's health

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DESTRUCTION; BONE MASS; BREAST CANCER; CALCIUM INTAKE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; FOLLOW UP; FRACTURE; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; LIFESTYLE MODIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT ADVOCACY; PATIENT CARE; PATIENT COUNSELING; POSTMENOPAUSE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SURVIVOR; TREATMENT RESPONSE; VITAMIN INTAKE;

EID: 84938422666     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: 10.11138/ccmbm/2014.11.2.110     Document Type: Short Survey

References (26)

1. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299-309.
2. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26(33):5465-76.
3. Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P. Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol. 2008;47(4):747-54.
4. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125(1-2):13-22.
5. National Osteoporosis Foundation (2008) NOF Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/ clinical-guidelines. Accessed September 15, 2011.
6. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-57.
7. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18(11):1439-50.
8. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34 Suppl 1:S3-18.
9. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009;7 Suppl 3:S1-32; quiz S33-5.
10. Rizzoli R, Body JJ, De Censi A, Reginster JY, Piscitelli P, Brandi ML. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int. 2012;23(11):2567-76.
11. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/ index.jsp. Accessed March 15, 2013.
12. National Osteoporosis Guideline Group (2010) NOGG Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. http://www.shef.ac.uk/NOGG/. Accessed September 15, 2011.
13. Dachverband Osteologie. DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie. 2011;20:55-74.
14. Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin. 2010;26 Suppl 3:3-20.
15. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABC-SG-12 randomised trial. Lancet Oncol. 2011;12(7):631-41.
16. Clemons M, Russell K, Costa L, Addison CL. Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated? Breast Cancer Res Treat. 2012;134(2):453-7.
17. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA. 2002;288(18):2300-6.
18. Cornuz J, Feskanich D, Willett WC, Colditz GA. Smoking, smoking cessation, and risk of hip fracture in women. Am J Med. 1999;106(3):311-4.
19. National Osteoporosis Foundation guideline. Excerpta Medica, Inc; Belle Mead, NJ: 1999. Physicians guide to prevention and treatment of osteoporosis.
20. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
21. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-73.
22. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. 2011;22(12):2546-55.
23. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188-94.
24. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-9.
25. Llombart A. Oncology 2009 Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA [Abstract 213].
26. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677-92.